QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

QURE

QT54uniQure N.V.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
46.29
-1.87-3.88%
OverviewShort InterestFilings
QUREQT54uniQure N.V.·NASDAQ
OverviewShort InterestFilings
46.29-3.88%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.51
Insider Own3.77%
Shs Outstand63.07M
Perf Week72.60%
Market Cap2.98BForward P/E-EPS next Y-3.05Insider Trans-0.18%Shs Float-Perf Month87.48%
Enterprise Value2.90BPEG-EPS next Q-0.88Inst Own-Short Float-Perf Quarter203.34%
Income-209997195.00P/S164.63EPS this Y0.03%Inst Trans-Short Ratio-Perf Half Y111.47%
Sales18.09MP/B19.84EPS next Y13.22%ROA-26.82%Short Interest-Perf YTD93.44%
Book/sh2.36P/C-EPS next 5Y-ROE-145.81%52W High71.50 -35.26%Perf Year212.98%
Cash/sh9.31P/FCF-EPS past 3/5Y-ROIC-26.48%52W Low8.73 430.24%Perf 3Y-
Dividend Est.-EV/EBITDA-22.47Sales past 3/5Y-46.76% -15.89%Gross Margin74.14%Volatility21.88% 11.72%Perf 5Y-
Dividend TTM-EV/Sales160.39EPS Y/Y TTM29.27%Oper. Margin-1057.48%ATR (14)3.45Perf 10Y-
Dividend Ex-Date-Quick Ratio10.40Sales Y/Y TTM-29.63%Profit Margin-1154.42%RSI (14)78.81Recom2.33
Dividend Gr. 3/5Y-Current Ratio10.40EPS Q/Q-3.66%SMA2060.75%Beta-0.15Target Price53.56
Payout0.00%Debt/Eq0.42Sales Q/Q100.00%SMA5091.87%Rel Volume2.25Prev Close48.16
Employees209LT Debt/Eq2.68EarningsAug 04SMA20068.14%Avg Volume2.15MPrice46.29
IPO DateFeb 05, 2014Option/ShortYes / YesEPS/Sales Surpr.3.41% -20.00%Net Debt/EBITDA0.59Volume4,848,803Change-3.88%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-18-26ReiteratedRBC CapitalOutperform$35 → $65
Jun-18-26ReiteratedBarclaysEqual Weight$31 → $65
Jun-18-26ReiteratedLeerink PartnersOutperform$35 → $70
Jun-18-26ReiteratedGoldman SachsNeutral$14 → $46
Jun-17-26ReiteratedCantor FitzgeraldNeutral$47 → $61
May-06-26ReiteratedH.C. WainwrightBuy$70 → $50
May-05-26ReiteratedStifel NicolausBuy$14 → $28
Apr-30-26ReiteratedChardan CapitalBuy$31 → $37
Apr-20-26ReiteratedGoldman SachsNeutral$38 → $10
Mar-11-26UpgradeMizuhoNeutral → Outperform
Latest News
Jun-18-26
Jun-18-2610:06AM
UniQure: AMT-130's FDA Path Reaffirms My Bull CaseSeekingAlpha
09:48AM
Sarepta: Caution Still Warranted Despite FDA's Gene Therapy-Friendly StanceSeekingAlpha
Jun-17-26
Jun-17-2607:00PM
Top movers in Wednesday's sessionChartMill
04:30PM
These stocks are moving in today's sessionChartMill
03:40PM
uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock SoaringSeekingAlpha
02:30PM
Gapping stocks in Wednesday's sessionChartMill
01:06PM
12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga
12:30PM
Discover the top movers in Wednesday's pre-market session.ChartMill
12:06PM
Crude Oil Edges Higher; US Retail Sales Top EstimatesBenzinga
10:11AM
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On WednesdayBenzinga
08:06AM
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga
07:07AM
uniQure To Submit BLA In Q3 2026 For AMT‑130 Huntington's Therapy After FDA Accepts 3‑Year Phase I/II Data As Basis For Accelerated ApprovalBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue191627
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A4218
Gross Profit13149
Selling, General and Administrative Excl. Other726551
Research and Development132141144
Other Operating Expense0-4-2
Operating Income-191-188-184
Interest Expense626264
Unusual Expense
———
Non-Operating Income (Expense)-49-56-11
Net Income Before Taxes-203-193-237
Income Taxes562
Consolidated Net Income-210-199-240
Net Income From Continuing Operations-210-199-240
Net Income-210-199-240
EPS (Recurring)-3.51-3.46-4.92
EPS (Basic, Before Extraordinaries)-3.51-3.46-4.92
EPS (Diluted)-3.51-3.46-4.92
EBITDA-129-117-161
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio153.4986.75—
Gross Margin68.4287.5033.33
Operating Margin-1,005.26-1,175.00-681.48
Net Margin-1,105.26-1,243.75-888.89
Shares Outstanding635849
Market Capitalization2,9161,388—
Operating Lease Expense
———
Insider Trading Volume
$49.21$43.88$38.55$33.23$27.90● Close Price0.00M2.58M5.16M7.75M10.33MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Balachandran MadhavanDirectorJun 15 '26Sale27.8510,000278,50043,254Jun 17 12:00 AM
Balachandran MadhavanDirectorJun 15 '26Option Exercise8.4920,000169,80053,254Jun 17 12:00 AM
Potts JeannetteChief Legal OfficerJun 15 '26Sale27.675,237144,908133,246Jun 17 12:00 AM
Jacques Rachelle SuzanneDirectorJun 11 '26Sale27.061,99353,93133,903Jun 12 12:00 AM
Meek David D.DirectorJun 11 '26Sale27.061,99353,93139,747Jun 12 12:00 AM
Springhorn Jeremy P.DirectorJun 11 '26Sale27.061,99353,93143,251Jun 12 12:00 AM
Balachandran MadhavanDirectorJun 11 '26Sale27.061,99353,93143,254Jun 12 12:00 AM
Gut RobertDirectorJun 11 '26Sale27.062,72673,76632,259Jun 12 12:00 AM
POST LEONARD EDirectorJun 11 '26Sale27.061,99353,93135,494Jun 12 12:00 AM
Kaye JackDirectorJun 11 '26Sale27.061,99353,93125,996Jun 12 12:00 AM
O'Keefe KylieChief Customer & Strat OfficerJun 11 '26Sale27.0615,936431,228108,864Jun 12 12:00 AM
Gut RobertDirectorJun 10 '26Option Exercise16.045,29084,85234,987Jun 12 12:00 AM
Gut RobertDirectorJun 10 '26Sale26.057,552196,72027,435Jun 12 12:00 AM
Kaye JackDirectorJun 03 '26Option Exercise16.045,29084,85223,084Jun 05 12:00 AM
Kaye JackDirectorJun 03 '26Sale30.012,64579,37620,439Jun 05 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR